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Essential surgery is cost eﬀ ective in resource-poor countries 
In this issue of The Lancet Global Health, Tiﬀ any Chao 
and colleagues present a systematic, comprehensive, 
and critical assessment of published estimates of 
the cost-eﬀ ectiveness of essential surgery,1 and thus 
make an important contribution to the published 
work on the economics of global health interventions. 
Their headline ﬁ nding is that a wide range of surgical 
interventions are cost eﬀ ective across a wide range of 
settings in low-income and middle-income countries, 
and are competitive with other accepted and broadly 
implemented interventions. The problems of varying 
study quality and the diﬃ  culty of comparing costs 
and outcomes between studies are real. Some of the 
estimates are more  inclusive and thus more defensible 
than others. Although work should continue to 
harmonise cost estimates in global health programmes 
generally, these methodological issues are not speciﬁ c 
to surgery and they should not obscure the central 
ﬁ ndings of this study. Debates about surgery’s place in 
the ranks of primary health-care options compared with 
infectious disease interventions, and about the relative 
prominence that should be given to so-called vertical 
delivery care models, are ultimately sterile and outdated. 
They should be replaced by increased emphasis on 
identiﬁ cation of value for money whatever the service 
delivery platform. With regard to surgery, this change 
means investment in surgical facilities equipped and 
staﬀ ed to provide a set of inexpensive and very eﬀ ective 
interventions. What that set of interventions should 
consist of will vary somewhat by country and Chao 
and colleagues’ study provides substantial guidance 
regarding which interventions are appropriate where. 
One of the barriers to investment in surgical capacity in 
low-income countries is the correct perception that they 
require a substantial up-front expenditure in facilities, 
equipment, and training. However, the scientiﬁ c literature 
assessed by Chao and co-workers suggests that when 
these initial capital costs are properly amortised over 
their useful life and across realistic surgical volumes, the 
initial investments are, in reality, modest. Furthermore, 
the return-on-investments in surgery might be greater 
than would be suggested by the cost-eﬀ ectiveness results 
for each individual intervention type. Potential positive 
externalities exist in the form of upgraded general surgical 
capacity resulting from a focus on one type of surgery. 
Chao and colleagues mention the case of missions to 
deliver cleft lip and palate repair that result in precisely 
this type of development of local surgical capacity. Such 
positive spillover eﬀ ects have also been presented as part 
of the rationale for widespread adoption of antiretroviral 
therapy for the treatment of HIV. Evidence for these 
eﬀ ects with regard to antiretroviral therapy is sparse and 
somewhat equivocal.2–4 Nevertheless, the presence of such 
eﬀ ects is plausible, warrants further investigation, and, if 
conﬁ rmed, could substantially increase the attractiveness 
of investments in surgical platforms in resource-poor 
countries.
Two countries are notable for their near absence in the 
published work—India and China. Chao and colleagues1 
identiﬁ ed only one study for each country, on cataract 
repair. Understanding the cost-eﬀ ectiveness of surgery 
in these two countries, which account for such a large 
portion of the global burden of disease, is an obvious 
priority area for additional research.
A strength of this study1 is that Chao and colleagues 
took pains to place the cost-eﬀ ectiveness ratios in context. 
Many recently published cost-eﬀ ectiveness analyses 
in global health merely state whether the intervention 
assessed meets the WHO deﬁ nition of a cost-eﬀ ectiveness 
ratio of lower than a country’s gross domestic product 
per head for very cost eﬀ ective and of one-to-three 
times greater than the country’s gross domestic product 
per head for cost eﬀ ective.5–7 Besides setting such a low 
bar for cost-eﬀ ectiveness that almost any intervention 
with measurable beneﬁ ts will be cost eﬀ ective, the 
WHO threshold provides little guidance to decision 
makers who may need to confront diﬃ  cult trade-oﬀ s in 
choosing among options, all of which meet the nominal 
cost-eﬀ ectiveness threshold. Nevertheless, reference to 
the WHO threshold is common and in this study nearly 
all of the surgical options were “very cost eﬀ ective” by 
WHO criteria. Fortunately, the authors position their 
ﬁ ndings alongside far more useful comparators, namely 
a set of scaled-up interventions for which governments 
in resource-poor countries have shown a willingness to 
pay and whose public health eﬀ ects are well documented. 
These interventions include antiretroviral therapy for HIV, 
BCG vaccine for tuberculosis prevention, vaccination for 
other childhood diseases, and the provision of bednets for 
the prevention of malaria. 
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The use of the Drummond checklist to assess study 
quality is of limited value, and is more helpful as a 
guide to authors than as a reliable way to assess internal 
validity. Each item on the checklist receives equal 
weight, whereas in reality some are more important 
than others, or are even so diﬀ erent that they should 
not be included on the same scale. For example, the 
question “Were the costs valued credibly?” invites 
assessment of numerous issues that could easily 
constitute a checklist in itself. The question “Were 
costs adjusted for diﬀ erential timing?”, by contrast, is 
a more restrictive and typically a far less consequential 
issue. The latter is about as important as the issue of the 
proper use of discounting, which is omitted from the 
Drummond checklist altogether. Thus, as a guide to the 
critical reader, the ﬁ nal checklist score attached to each 
study is far less informative than the assessment of each 
study’s rating on each of the ten questions considered 
individually. 
Whereas a need exists for additional validated 
techniques for assessment of internal validity, far less 
work has been done on development of techniques for 
assessment of external validity. What are the variables 
that determine whether the beneﬁ ts from surgery 
measured by the relative risk reduction of a relevant 
undesirable outcome or condition will be replicated 
in another setting? Local economic indices (ie, gross 
domestic product), epidemiology of the surgical disease, 
and cost of requisite human and material resources 
are some of the many factors that can determine the 
scalability of the intervention. Progress in understanding 
external validity would confer two kinds of reward. On 
the one hand, it would allow researchers and decision 
makers tasked with choosing programme and policy 
options to select those that are likely to have high 
eﬀ ectiveness in the relevant setting. On the other hand, 
development of such an external validity assessment 
technique for surgery implies the identiﬁ cation of 
factors, the presence of which are associated with 
high eﬀ ectiveness. Modiﬁ cation of factors that are 
manipulable such as task sharing, task shifting, and 
other manpower choices; provider or patient incentives; 
or the role of outreach and publicity, thus helps to guide 
programme design.
Cost-eﬀ ective surgical interventions are increasingly 
recognised as important contributors in the developing 
global health landscape, as the burden of disease from 
non-communicable diseases and injury rises. More 
high-quality primary research on eﬀ ectiveness, coupled 
with economic analysis, is needed to determine which 
interventions are right for which target populations. 
Structural barriers that are unique to implementation 
of surgical treatments will require innovations in 
delivery models. Despite these challenges, Chao and 
colleagues1 have provided a strong conﬁ rmation of the 
promise of surgery as a vital technique in the future 
armamentarium of global health.
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